Molecular structure of Cinoxacin, CAS Number: 28657-80-9
Cinoxacin (CAS 28657-80-9)
See product citations (2)
Alternate Names:
Cinoxacino; Cinoxacinum; Clinoxacin
Application:
Cinoxacin is an antibacterial quinolone
CAS Number:
28657-80-9
Purity:
≥99%
Molecular Weight:
262.22
Molecular Formula:
C12H10N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cinoxacin is an antibacterial quinolone analog of oxolinic acid. The compound has been documented to block DNA synthesis through inhibition of Topo II (DNA gyrase) as well as topoisomerase IV. Cinoxacin has been observed to block both topoisomerse IV in both prokaryotic and eukaryotic cell lines. Due to the inhibiting activity of Cinoxacin the compound has displayed toxicity against eukaryotic cells. In vitro studies have shown the renal damage caused by Cinoxacin to be attributed to deposition of Cinoxacin crystals in the urinary tract.
Cinoxacin (CAS 28657-80-9) References
- Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. | Lumish, RM. and Norden, CW. 1975. Antimicrob Agents Chemother. 7: 159-63. PMID: 1094949
- Absence of cinoxacin-induced DNA fragmentation and mutations in the rat granuloma pouch. | Pino, A., et al. 1989. Environ Mol Mutagen. 13: 112-5. PMID: 2917551
- The effect of nalidixic acid, cinoxacin, and beta-cyanoalanine on cultured chondrocytes. | Atencia, LJ., et al. 1988. Arthritis Rheum. 31: 455-6. PMID: 3358808
- Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. | Barry, AL., et al. 1984. Antimicrob Agents Chemother. 25: 633-7. PMID: 6233935
- Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections. | Sisca, TS., et al. 1983. Drugs. 25: 544-69. PMID: 6347618
- Time-dependent elimination of cinoxacin in rats. | Koike, M., et al. 1984. J Pharm Sci. 73: 1697-700. PMID: 6527237
- Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. | Scavone, JM., et al. 1982. Pharmacotherapy. 2: 266-72. PMID: 6763208
- Cinoxacin: competitive inhibitory effect on p-aminohippurate transport and its uptake in renal cortical slices. | Gemba, M., et al. 1983. Arch Int Pharmacodyn Ther. 261: 308-15. PMID: 6838288
- A comparison of cinoxacin and co-trimoxazole in the treatment of cystitis. | Schneider, RE. 1982. Clin Ther. 4: 510-4. PMID: 6980051
- Influence of urinary pH on the pharmacokinetics of cinoxacin in humans and on antibacterial activity in vitro. | Barbhaiya, RH., et al. 1982. Antimicrob Agents Chemother. 21: 472-80. PMID: 7103450
- Cinoxacin in urinary tract infections. Theoretical and practical considerations. | Madsen, PO., et al. 1981. Urology. 17: 496-9. PMID: 7233671
- In vitro activity of cinoxacin, ampicillin, and chloramphenicol against Shigella and nontyphoid Salmonella. | Rubinstein, E. and Shainberg, B. 1977. Antimicrob Agents Chemother. 11: 577-9. PMID: 856008
- DNA gyrase, topoisomerase IV, and the 4-quinolones. | Drlica, K. and Zhao, X. 1997. Microbiol Mol Biol Rev. 61: 377-92. PMID: 9293187
Inhibitor of:
Topo II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cinoxacin, 50 mg | sc-202543 | 50 mg | $100.00 | |||
Cinoxacin, 250 mg | sc-202543A | 250 mg | $320.00 |